Skip to main
NMRA
NMRA logo

NMRA Stock Forecast & Price Target

NMRA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 13%
Hold 38%
Sell 13%
Strong Sell 0%

Bulls say

Neumora Therapeutics Inc. is positioned for strong growth, with projected U.S. sales reaching $250 million by 2030 and $950 million by 2035, aligning with market consensus. Its lead asset, Navacaprant, is anticipated to be successful in its Phase 3 program for Major Depressive Disorder (MDD), with a sales potential of $750 million by 2028 and a peak estimate of $3 billion. Additionally, the company’s focus on innovative approaches to underserved neuropsychiatric and neurodegenerative disorders positions it for significant long-term shareholder value.

Bears say

Neumora Therapeutics Inc has faced significant setbacks, notably the failure of the KOASTAL-1 study and the discontinuation of aticaprant development by Johnson & Johnson, which contribute to ongoing concerns regarding the stock's performance. Although management has made changes and there is cautious optimism about the K2/K-3 studies, lack of conviction surrounding their outcomes raises doubts about the company's ability to successfully advance its pipeline. This combination of project failures and uncertainty about future studies creates a challenging environment for investor confidence.

NMRA has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neumora Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neumora Therapeutics Inc (NMRA) Forecast

Analysts have given NMRA a Buy based on their latest research and market trends.

According to 8 analysts, NMRA has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neumora Therapeutics Inc (NMRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.